Here’s what you need to know:
1. Of the 378 patients in the five lanreotideautogel/depot trials the researchers pooled data from, 90 percent received lanreotideautogel/depot of 120 milligrams.
2. The adverse event profiles were overall similar across all of the studies; the most commonly reported adverse event were GI events (56 percent).
3. There were no study withdrawals due to GI adverse events and no deaths in the studies were considered treatment-related.
The researchers concluded: “This comprehensive safety analysis supports the positive benefit–risk profile of LAN both for CS control in symptomatic NET and for tumor control in metastatic intestinal/pancreatic NET.”
More articles on gastroenterology and endoscopy:
AGA, partners a step closer to developing CME to improve IBD management
Digestive diseases led to 20.4M ambulatory surgical procedures in 2010: 5 key statistics
Is fecal transplantation effective? 3 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
